EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacological treatments in disorders of consciousness

Christian Saleh iD, Fatemeh Seyfzadeh iD, Emilie Szymkowicz, Naji Alnagger iD, Tatiani Soultana Ilia, Alexandra A Oancea, Olivia Gosseries iD

Brain Communications · 31.10.2026 · 8 (6)

DOI: 10.1093/braincomms/fcag369 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain Communications, online erschienen am 06.10.2026. Verfasst von Christian Saleh und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Basel, 4001 Basel, Switzerland. Die Arbeit nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University and University Hospital of Liege, Belgian National Funds for Scientific Research, FNRS Incentive Grant for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disorders of consciousness (DoC) are among the most severe and devastating neurological conditions. The poorly understood underlying pathophysiology of DoC renders the search for adequate treatment options particularly difficult. The aim of this narrative review is to provide an overview of currently available pharmacological treatments, report the limitations of current research and discuss future directions, notably potential new treatments, advances in modelling approaches, potential mechanisms of action and the development of a standardized registry. We review pharmacological treatments that promote the recovery of consciousness in patients with DoC acting on dopaminergic (amantadine, levodopa, apomorphine, methylphenidate, bromocriptine, modafinil and selegiline) and GABAergic (zolpidem, baclofen and midazolam) pathways, as well as other pharmacological treatments (tricyclic antidepressants, anticonvulsants and simvastatin) and the combination of different treatments. The literature includes a limited number of randomized controlled trials (RCTs) alongside a large body of retrospective studies and case reports, which are classified as class IV evidence. Reported improvements in arousal or responsiveness are inconsistent, reflecting marked heterogeneity in patient populations, dosing regimens and outcome measures. Risk-of-bias assessment indicated that 12 of 22 RCTs (∼55%) exhibit some concerns or a high risk of bias. Multiple correspondence analysis yielded a descriptive mapping of RCT characteristics, demonstrating how pharmacological trials in DoC are grouped. Although mechanistic hypotheses converge on dopaminergic, GABAergic and thalamocortical modulation, the current literature on pharmacological treatments in DoC remains poorly reproducible. Given the significant methodological variability (e.g. study design, patient characteristics and outcome measures) across studies, current evidence does not allow firm conclusions regarding the most effective consciousness-enhancing pharmacological treatments in DoC. To make informed decisions in terms of pharmacological treatments and move towards personalized care for patients with DoC, rigorously designed multicentre controlled trials with harmonized outcome measures conducted with mechanistic and computational approaches are required. This can be achieved through an international registry to standardize data collection and improve reproducibility and replicability.

Schlagwörter

Stichwörter der Autor:innen

comaminimally conscious statepharmacologyunresponsive wakefulness syndromevegetative state

Autor:innen und Institutionen

  • University of Basel, 4001 Basel, Switzerland.
  • Coma Science Group, GIGA-Consciousness, GIGA Institute, University of Liège, 4000 Liège, Belgium.
  • NeuroRehab & Consciousness Clinic, Neurology Department, University Hospital of Liège, 4000 Liège, Belgium.
  • NeuroRecovery Lab, GIGA-Consciousness, GIGA Institute, University of Liège, 4000 Liège, Belgium.
  • Division of Neuropediatrics, Development and Rehabilitation, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
  • Department of Neurology, University Hospital of Basel, 4031 Basel, Switzerland.

ORCID-Profile: Christian Saleh, Fatemeh Seyfzadeh, Naji Alnagger, Olivia Gosseries

Förderung

  • University and University Hospital of Liege
  • Belgian National Funds for Scientific Research
  • FNRS Incentive Grant for Scientific Research
  • BIAL Foundation
  • fund Generet
  • King Baudouin Foundation
  • Mind Science Foundation
  • Fondation Léon Fredericq

Zitieren

APA

Saleh, C., Seyfzadeh, F., Szymkowicz, E., Alnagger, N., Ilia, T. S., Oancea, A. A., & Gosseries, O. (2026). Pharmacological treatments in disorders of consciousness. Brain Communications, 8(6). https://doi.org/10.1093/braincomms/fcag369

Vancouver

Saleh C, Seyfzadeh F, Szymkowicz E, Alnagger N, Ilia TS, Oancea AA, et al. Pharmacological treatments in disorders of consciousness. Brain Communications. 2026;8(6). doi:10.1093/braincomms/fcag369

BibTeX
@article{Saleh2026,
  author = {Saleh, Christian and Seyfzadeh, Fatemeh and Szymkowicz, Emilie and Alnagger, Naji and Ilia, Tatiani Soultana and Oancea, Alexandra A and Gosseries, Olivia},
  title = {Pharmacological treatments in disorders of consciousness},
  journal = {Brain Communications},
  year = {2026},
  volume = {8},
  number = {6},
  doi = {10.1093/braincomms/fcag369}
}
Kostenlos starten →